17 research outputs found
New aspects of supportive care: The MASCC vision
Get PDFThe Multinational Association of Supportive Care in Cancer (MASCC) was founded in 1991, and joined forces with the International Society of Oral Oncology (ISOO) in 1998. The "mission" of MASCC is to optimize supportive care in cancer patients worldwide, stimulate multi-disciplinary research, encourage international scientific exchange of information, expand professional expertise in supportive care, educate health care professionals worldwide in supportive care, and to serve as a resource for patients, families, and caregivers. Ten years ago, the most frequently addressed supportive care symptoms included pain, febrile neutropenia, and the prevention of nausea and vomiting. These topics are still indeed relevant for cancer patients, but today focus has also turned to topics such as mucositis, and specific supportive care problems in the elderly. Recent, studies have indicated that individually targeted supportive care therapy might become an important part of clinical practice in the near future
Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference
No full text
Measuring adverse event rates in oncology inpatients using trigger tools: An assessment of measurement properties.
No full textAntiemetic use of olanzapine in patients with advanced cancer:results from an open-label multicenter study
No full textErratum to:2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy (Supportive Care in Cancer, (2017), 25, 1, (289-294), 10.1007/s00520-016-3365-1)
No full textErratum to:2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy (Supportive Care in Cancer, (2017), 25, 1, (289-294), 10.1007/s00520-016-3365-1)
No full textDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
No full textENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
No full text
